Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations

Journal of Clinical Oncology

Volumn 28, Issue 34, 2010, Pages

  Chung, Kuei Pin ^a   Shih, Jin Yuan ^a   Yu, Chong Jen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; NAVELBINE; RNA;

ADJUVANT THERAPY; AGED; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENE MUTATION; GERIATRIC PATIENT; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; MULTIPLE CYCLE TREATMENT; POINT MUTATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; TREATMENT RESPONSE; TUMOR BIOPSY;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; CHEMOTHERAPY, ADJUVANT; CHOLECYSTITIS; CISPLATIN; COMBINED MODALITY THERAPY; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, ERBB-1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENTAL FINDINGS; LUNG NEOPLASMS; MUTATION; NEOPLASM STAGING; PEDIGREE; PNEUMONECTOMY; QUINAZOLINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VINBLASTINE;

EID: 79951881580     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.6260     Document Type: Article

References (17)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
2. Wu SG, Chang YL, Hsu YC, et al: Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. Oncologist 13:1276-1284, 2008
3. Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174, 2008
4. Hirsch FR, Scagliotti GV, Langer CJ, et al: Epidermal growth factor family of receptors in preneoplasia and lung cancer: Perspectives for targeted therapies. Lung Cancer 41:S29-S42, 2003 (suppl 1) (Pubitemid 36818993)
5. Prudkin L, Tang X, Wistuba II: Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer. J Thorac Oncol 4:139-141, 2009
6. Tang X, Shigematsu H, Bekele BN, et al: EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 65:7568-7572, 2005 (Pubitemid 41297226)
7. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
8. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004 (Pubitemid 38720929)
9. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004 (Pubitemid 39209661)
10. Yang CH, Yu CJ, Shih JY, et al: Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 26:2745-2753, 2008
11. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792, 2005 (Pubitemid 40271173)
12. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73, 2005
13. Chen Z, Feng J, Saldivar JS, et al: EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: One-third of doublets occur at five pairs of amino acids. Oncogene 27:4336-4343, 2008 (Pubitemid 352010002)
14. Bell DW, Gore I, Okimoto RA, et al: Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37:1315-1316, 2005 (Pubitemid 41722184)
15. Ikeda K, Nomori H, Mori T, et al: Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. Ann Thorac Surg 85:1430-1432, 2008 (Pubitemid 351381643)
16. Wellcome Trust Sanger Institute: Catalogue of somatic mutations in cancer. http://www.sanger.ac.uk/genetics/CGP/cosmic
17. Janne PA, Borras AM, Kuang Y, et al: A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 12:751-758, 2006 (Pubitemid 43259854)